- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03053739
To Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis (BosSilSS)
Randomized Controlled Trial to Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
All patients fulfilling the SSc classification criteria of American College of Rheumatology during the study period will be screened for presence of PAH. Diagnosed cases of PAH based on CD echo with PAP >35mmHg based on echocardiography will be enrolled in study.Baseline NYHA functional class and 6 min walk distance in meters will be assessed. Heamogram and LFT will be measured Patients will be assessed at two weeks for side effects/safety issues. 6MWT and NYHA functional class will be reassessed at 3 months and 6 months.2D echo will be done at 6 months to measure mPAP RandomizationAll eligible patients will be randomized in a 1:1 ratio in blocks of ten between the two arms. Randomization will be stratified based on severity of PAH. The drugs will be labelled as A and B randomly by another staff member, who will not be involved in deciding the treatment of the study subjects. The randomization sequence will be generated using computer random number generator.
Blinding will be ensured by matching placebo for ERA in one group and will labelled one treatment arm as 'A' and other treatment arm as 'B'. Allocation concealment will be ensured by means of enclosing the randomization sequence in sealed opaque envelopes. Sealed opaque envelopes will contain Code 'A' or Code 'B'.
Intervention-The study consists of two treatment arms. The study drugs mainly Bosentan and Placebo will be packed into matching tablets at the dosage 62.5 mg. One treatment arm will contain Sildenafil and Placebo while other treatment arm will contain Sildenafil and Bosentan. Treatment will be initiated as 20 mg twice a day for Sildena-fil in combination with placebo once a day in one treatment arm and with Bosentan 62.5 mg once a day in other treatment arm .Dose of Sildenafil will be increased to 20 mg thrice a day at four weeks and that of Bosentan to 62.5 mg twice a day. Placebo will be also be provided twice a day.This will be continued till end of study period.. Dose adjustments in case of adverse events will be made depending on the severity of adverse events.
Statistical analysis- Intention to treat analysis will be carried for the primary and secondary outcomes. For continuous outcomes, unpaired t-test and for dichotomous outcomes chi-squares test with Yate's correction will be used. P<0.05 will be considered significant
Studietyp
Inskrivning (Förväntat)
Fas
- Fas 4
Kontakter och platser
Studiekontakt
- Namn: Preksha Dwivedi, M D
- Telefonnummer: +91-8109492343
- E-post: drpreksha07@gmail.com
Studera Kontakt Backup
- Namn: Shefali Sharma, M.D
- Telefonnummer: +91-9417372439
- E-post: sharmashefali@hotmail.com
Studieorter
-
-
-
Chandigarh, Indien, 160012
- Rekrytering
- Dr Preksha Dwivedi
-
Kontakt:
- Preksha Dwivedi, MD
- Telefonnummer: +91-8109492343
- E-post: drpreksha07@gmail.com
-
Kontakt:
- Shefali Sharma, MD
- Telefonnummer: +91-9417372439
- E-post: Sharmashefali@hotmail.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Male or female patients aged 18 years
- Patients with systemic sclerosis
- PAH diagnosed as PAP>35mmHg
- NYHA functional class II,III,IV
- SSc disease duration >1years
Exclusion Criteria:
- Forced vital capacity <60% predicted
- Renal insufficiency
- Left heart disease and other relevant cardiac conditions
- Pregnant or breastfeeding female
- Patients on PAH specific therapy
- Liver disease
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Combination arm A-Sildenafil and Bosentan
Combination Arm A -Intervention- Drug
|
Sildenafil 20 mg three times a day and bosentan 62.5mg two times a day
|
Placebo-jämförare: Monotherapy arm-Sildenafil and Placebo
Monotherapy arm B Intervention-Drugs Tab Sildenafil 20mg- three times a day for 6 months, and Placebo tab (matched for bosentan) for 6 months
|
Sildenafil 20 mg three times a day and placebo (matched for bosentan)two times a day
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Change in Pulmonary artery pressures
Tidsram: Baseline and 6 months
|
Change in Pulmonary artery pressures measured by echocardiography at baseline and 6 months in patients of systemic sclerosis with PAH when treatment with Single(PDE-5inhibitors at dose of 20 mg maximum upto 60mg) versus Dual therapy(PDE-5inhibitors and ER antagonist 62.5 mg maximum upto 125mg) for 6 months
|
Baseline and 6 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
1.Change in 6 Minute walk distance
Tidsram: Baseline and 6 months
|
1. To compare change in 6 MWD at baseline, and 6 months when treated with single versus dual therapy.
|
Baseline and 6 months
|
Time To Clinical Worsening (TTCW)
Tidsram: Baseline and 6 months
|
To compare time to clinical worsening (TTCW) in SSc patients when treated with single versus dual therapy.
TTCW is defined as first occurrence of all cause deaths, PAH related hospitalisation, worsening of symptoms defined as a decrease of >15% in 6 min walk distance and worsening of NYHA functional class.
|
Baseline and 6 months
|
Emergent side effects of Sildenafil and Bosentan
Tidsram: Baseline to 6 months
|
To compare the emergent side effects of sildenafil and bosentan by way of comparison of serious and nonserious side effects.
|
Baseline to 6 months
|
Samarbetspartners och utredare
Utredare
- Studiestol: Nandita Kakker, M.D, Institutional ethics committee,PGIMER Chandigarh,India
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Patologiska processer
- Hjärt-kärlsjukdomar
- Kärlsjukdomar
- Hudsjukdomar
- Luftvägssjukdomar
- Lungsjukdomar
- Bindvävssjukdomar
- Hypertoni, lung
- Skleros
- Hypertoni
- Sklerodermi, systemisk
- Sklerodermi, diffus
- Pulmonell arteriell hypertoni
- Familjär primär pulmonell hypertoni
- Molekylära mekanismer för farmakologisk verkan
- Antihypertensiva medel
- Vasodilaterande medel
- Urologiska medel
- Enzyminhibitorer
- Fosfodiesterashämmare
- Fosfodiesteras 5-hämmare
- Endotelinreceptorantagonister
- Sildenafil Citrate
- Bosentan
Andra studie-ID-nummer
- MK/2927/DM/9430
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Sildenafil 20mg and Bosentan 62.5mg
-
Rigshospitalet, DenmarkAvslutadEisenmengers syndromDanmark
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI); National Center for...RekryteringPediatrisk pulmonell hypertoniFörenta staterna, Kanada
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São Paulo; Instituto do CoracaoAvslutadPulmonell arteriell hypertoni | Medfödd hjärtsjukdomBrasilien
-
Shandong UniversityWest China Second University HospitalHar inte rekryterat ännuIhållande pulmonell hypertoni hos nyföddaKina
-
All India Institute of Medical Sciences, New DelhiOkändPulmonell hypertoni sekundärt till lungsjukdom och/eller hypoxiIndien
-
ActelionAvslutadPulmonell arteriell hypertoniFörenta staterna
-
Hospital Universitari Vall d'Hebron Research InstituteOkändPulmonell hypertoniSpanien
-
Amsterdam UMC, location VUmcOkändPulmonell arteriell hypertoniNederländerna
-
University of Mississippi Medical CenterAvslutadVaskulär funktion | RasskillnadFörenta staterna
-
Novartis PharmaceuticalsAvslutadPulmonell arteriell hypertoniTyskland, Belgien, Förenta staterna, Litauen, Storbritannien, Italien, Australien